Patents Assigned to Sharp
-
Patent number: 11419817Abstract: This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.Type: GrantFiled: April 5, 2018Date of Patent: August 23, 2022Assignee: Merck Sharp & Dohme LLCInventors: Stephanie Elizabeth Barrett, Marian E. Gindy, Li Li, Ryan S. Teller, Seth P. Forster
-
Patent number: 11424874Abstract: A terminal apparatus for communicating with a base station apparatus, the terminal apparatus including: a receiver configured to receive information related to subcarrier spacing for an OFDM signal from the base station apparatus; and a transmitter configured to transmit an uplink data channel to the base station apparatus by using the OFDM signal, based on the information related to the subcarrier spacing. The transmitter generates the OFDM signal by using a plurality of the subcarrier spacings, and the transmitter configures a transmit power of the uplink data channel, based on the subcarrier spacing of subcarriers to which the uplink data channel has been mapped.Type: GrantFiled: December 21, 2017Date of Patent: August 23, 2022Assignees: SHARP KABUSHIKI KAISHA, FG Innovation Company LimitedInventors: Takashi Yoshimoto, Jungo Goto, Osamu Nakamura, Yasuhiro Hamaguchi
-
Patent number: 11422412Abstract: A liquid crystal panel includes a first substrate including multiple pixel electrodes; a liquid crystal layer; and a second substrate including a common electrode. In at least 30 pixels consecutive in a row direction, arrays of the domains are identical, the domains in the display unit region located in an nth row are arranged in an order of a first domain, a second domain, a third domain, and a fourth domain, and each of the pixel electrodes includes a first pixel electrode having a configuration in which fine slits parallel to an alignment vector of the corresponding domain are provided in at least one of a region superimposed on the first domain, a region superimposed on the second domain, a region superimposed on the third domain, or a region superimposed on the fourth domain while the fine slits are not provided in the remaining regions.Type: GrantFiled: February 22, 2021Date of Patent: August 23, 2022Assignee: SHARP KABUSHIKI KAISHAInventors: Fumikazu Shimoshikiryoh, Shinichi Terashita, Kouichi Watanabe
-
Patent number: 11424225Abstract: An image display device includes: a plurality of micro light emitting elements arranged in an array shape; a driving circuit substrate including a driving circuit that supplies electric current to the plurality of micro light emitting elements and that causes the plurality of micro light emitting elements to emit light; a plurality of micro lenses in contact with light emitting surfaces of the plurality of micro light emitting elements; and a plurality of partition walls disposed around the plurality of micro lenses in a direction parallel to the light emitting surfaces.Type: GrantFiled: July 1, 2020Date of Patent: August 23, 2022Assignee: Sharp Fukuyama Laser Co., Ltd.Inventors: Katsuji Iguchi, Hidenori Kawanishi, Koji Takahashi, Masumi Maegawa
-
Patent number: 11422359Abstract: A projector, a rotational phase control device, a program for the rotational phase control device, and a wheel rotational speed control method include: a phosphor wheel that emits a plurality of different color lights at a cycle corresponding to a rotational speed when excitation light is irradiated; a color wheel into which the lights emitted from phosphor wheel enter; and a rotational phase control device that controls a rotational speed and a phase of color wheel in accordance with a rotational speed and a phase of phosphor wheel so that a phase relationship between phosphor wheel and color wheel is not changed and so that a rotational speed ratio between phosphor wheel and color wheel is equal to a rotational speed ratio between phosphor wheel and color wheel in a steady state.Type: GrantFiled: December 5, 2017Date of Patent: August 23, 2022Assignee: SHARP NEC DISPLAY SOLUTIONS, LTD.Inventor: Takeshi Kato
-
Patent number: 11423856Abstract: An active matrix substrate includes a plurality of signal lines, each of which includes first and second line portions and an inner connection portion (connection portion) that connects the first and second line portions. The first and second line portions of one of two adjacent signal lines are made of first and second conductive layers, respectively, and the first and second line portions of the other of the two adjacent signal lines are made of second and first conductive layers, respectively. The position of the connection portion of each of the signal lines is determined in accordance with the layout position of that signal line in the line region.Type: GrantFiled: June 11, 2021Date of Patent: August 23, 2022Assignee: SHARP KABUSHIKI KAISHAInventor: Yohsuke Fujikawa
-
Publication number: 20220259227Abstract: The present invention relates to Tetracyclic Heterocycle Compounds of Formula and pharmaceutically acceptable salts or prodrug thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.Type: ApplicationFiled: February 14, 2022Publication date: August 18, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Timothy John Hartingh, John A. McCauley, Tao Yu, Yonglian Zhang
-
Publication number: 20220259188Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.Type: ApplicationFiled: June 1, 2020Publication date: August 18, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Hua Zhou, John J. Acton, III, Michael J. Ardolino, Yi-Heng Chen, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, William P. Kaplan, Solomon D. Kattar, Mitchell H. Keylor, Derun Li, Kaitlyn Marie Logan, Min Lu, Gregori J. Morriello, Santhosh F. Neelamkavil, Barbara Pio, Nunzio Sciammetta, Vladimir Simov, Jing Su, Luis Torres, Xin Yan
-
Publication number: 20220257762Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.Type: ApplicationFiled: February 11, 2022Publication date: August 18, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
-
Publication number: 20220259656Abstract: The present invention provides a blood biomarker and genetic markers on human chromosome 1 that are associated with a beneficial response to CRTH2 receptor antagonists. These combination of the blood biomarker and genetic markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with CRTH2 receptor antagonist compositions and drug products, in methods of treating patients having a disease susceptible to treatment with a CRTH2 receptor antagonist, e.g., asthma, and in methods for selecting the most appropriate therapy for such patients.Type: ApplicationFiled: April 28, 2020Publication date: August 18, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Devan V. Mehrotra, George Philip, Peter M. Shaw
-
Patent number: 11415696Abstract: An optical sensor for appropriately updating a crosstalk value is provided with: a photon-counting type of first light-receiving unit for receiving target object reflected light and cover panel reflected light; and a determination circuit that determines whether or not the target object reflected light is received by the first light-receiving unit, on the basis of a first received light pulse signal that is based on at least one of the target object reflected light and the cover panel reflected light, and a reference pulse signal.Type: GrantFiled: March 14, 2018Date of Patent: August 16, 2022Assignee: SHARP KABUSHIKI KAISHAInventors: Hideki Sato, Takuma Hiramatsu, Takayuki Shimizu, Yoshiki Ikuta
-
Patent number: 11416108Abstract: A display device includes a display area and a frame area surrounding the display area. The display device comprises a TFT layer, a light-emitting element layer, a sealing layer including a first inorganic sealing film, an organic sealing film, and a second inorganic sealing film, a bank coated with the first inorganic sealing film and the second inorganic sealing film, a touch panel function layer, and a plurality of touch panel wires running to intersect with the bank in planar view and connected to the touch panel function layer. The second inorganic sealing film includes a bank coating that coats an upper face of the bank, and a protrusion, in a clearance between neighboring two of the plurality of touch panel wires, protrudes from the bank coating toward the display area or away from the display area.Type: GrantFiled: July 25, 2018Date of Patent: August 16, 2022Assignee: SHARP KABUSHIKI KAISHAInventors: Masaki Yamanaka, Yi Sun, Masahiko Miwa, Takao Saitoh, Yohsuke Kanzaki, Seiji Kaneko
-
Patent number: 11419048Abstract: A User Equipment (UE) includes a transmitter configured to, in a case that, at a time when a Public Land Mobile Network (PLMN) is changed, a first timer is running for a certain Data Network Name (DNN) and an old PLMN but that a second timer is not running for the DNN or a new PLMN and is not deactivated, be capable of transmitting a PDU session establishment request message for the DNN or no DNN in the new PLMN without stopping the first timer for the DNN and the old PLMN. Thus, a communication control method is provided that is used in a case that, in 5G congestion control in which multiple types of congestion control are applied, the PLMN is changed during application of the congestion control.Type: GrantFiled: June 20, 2019Date of Patent: August 16, 2022Assignees: SHARP KABUSHIKI KAISHA, FG Innovation Company LimitedInventors: Masafumi Aramoto, Tsuyoshi Takakura
-
Patent number: 11417281Abstract: One of a plurality of data signal lines or one of a plurality of control lines that is electrically coupled to a first lead wiring line, and another one of the plurality of data signal lines or another one of the plurality of control lines that is electrically coupled to a second lead wiring line are adjacent to each other. The first lead wiring line is provided in a first metal layer. The second lead wiring line is provided in a second metal layer being a layer different from the first metal layer. The first lead wiring line and the second lead wiring line are superposed on one another through intermediation of an inorganic insulating film.Type: GrantFiled: March 30, 2018Date of Patent: August 16, 2022Assignee: SHARP KABUSHIKI KAISHAInventors: Makoto Yokoyama, Junichi Yamada
-
Patent number: 11415869Abstract: An electronic device includes blowers. Blowers cool liquid crystal panels for light modulation mounted on illumination optical system for outputting light to a projection lens, respectively, and are disposed on the opposite side to the side where the projection lens of three liquid crystal panels is disposed and are arranged side by side along a first direction facing two liquid crystal panels of three liquid crystal panels.Type: GrantFiled: May 25, 2018Date of Patent: August 16, 2022Assignee: SHARP NEC DISPLAY SOLUTIONS, LTD.Inventor: Ryosuke Kawase
-
Patent number: 11413352Abstract: The present disclosure provides conjugates which comprise an insulin molecule conjugated via a conjugate framework to one or more separate ligands that include a first saccharide, and wherein the conjugate framework also comprises a fatty chain (e.g., a C8-30 fatty chain). In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.Type: GrantFiled: December 13, 2018Date of Patent: August 16, 2022Assignee: Merck, Sharp & Dohme LLCInventors: Chris Moyes, Songnian Lin
-
Patent number: 11418941Abstract: A technique is provided that is related to a terminal apparatus, a base station apparatus, a communication method, and an integrated circuit which enable efficient communication. A terminal apparatus includes a receiver configured to receive, from a base station apparatus, a message requesting mobility history information, and a transmitter configured to notify the base station apparatus of the mobility history information, based on the message. The mobility history information includes a list including identifier information (first identifier information) of a cell of a first radio access technology, and a list including identifier information (second identifier information) of a cell of a second radio access technology. The mobility history information includes stay time information of a limited number of entries, each corresponding to a visit by the terminal apparatus in a cell and/or outside a network.Type: GrantFiled: April 2, 2019Date of Patent: August 16, 2022Assignees: SHARP KABUSHIKI KAISHA, FG INNOVATION COMPANY LIMITEDInventors: Hidekazu Tsuboi, Shohei Yamada, Takako Hori
-
Patent number: 11417851Abstract: A light-emitting element includes: a first electrode; a second electrode; a quantum dot layer including layered quantum dots between the first electrode and the second electrode; and a hole transport layer formed of LaNiO3 between the quantum dot layer and the first electrode.Type: GrantFiled: February 13, 2018Date of Patent: August 16, 2022Assignee: SHARP KABUSHIKI KAISHAInventors: Shinichi Handa, Yoshihiro Ueta, Noboru Iwata
-
Patent number: 11415854Abstract: A liquid crystal display device includes: a liquid crystal display panel having gate bus lines extending along a row direction and source bus lines extending along a column direction; and a gate bus line driving circuit and a source bus line driving circuit. The pixels are disposed in a pixel array region, which includes: a first region where arbitrary displaying takes place; and a second region where exclusively black displaying takes place, the second region adjoining the first region along the column direction. The gate bus lines include a first group of gate bus lines disposed in the first region and a second group of gate bus lines disposed in the second region. The second group of gate bus lines include a first gate bus line connected to the gate bus line driving circuit and second gate bus lines connected to the first gate bus line via an interconnect.Type: GrantFiled: June 25, 2021Date of Patent: August 16, 2022Assignee: SHARP KABUSHIKI KAISHAInventor: Yohichiroh Sakaki
-
Patent number: 11413292Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, Z, R1 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.Type: GrantFiled: February 11, 2019Date of Patent: August 16, 2022Assignee: Merck, Sharp & Dohme LLCInventors: Mark W. Embrey, Timothy John Hartingh, Marc Labroli, Izzat T. Raheem
